Comparative Pharmacology
Head-to-head clinical analysis: HEAVY SOLUTION NUPERCAINE versus NESACAINE MPF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEAVY SOLUTION NUPERCAINE versus NESACAINE MPF.
HEAVY SOLUTION NUPERCAINE vs NESACAINE-MPF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heavy solution nupercaine (dibucaine) is a potent, long-acting amide local anesthetic that stabilizes neuronal membranes by blocking voltage-gated sodium channels, thereby inhibiting the propagation of action potentials and preventing nerve impulse conduction.
Nesacaine-MPF (chloroprocaine) is an ester-type local anesthetic that stabilizes neuronal membranes by inhibiting sodium ion influx, thereby blocking impulse conduction in nerve fibers.
Spinal anesthesia: 0.5-1 mL of 0.5% heavy solution (2.5-5 mg) injected intrathecally; dose depends on level of anesthesia required.
1% solution: 2.5-30 mL (25-300 mg) subcutaneously or locally; maximum 30 mL per dose. 2% solution: 1.25-15 mL (25-300 mg) subcutaneously or locally; maximum 15 mL per dose.
None Documented
None Documented
Terminal elimination half-life is 2.5-4 hours (mean 3.5 h) in adults. In neonates, half-life is prolonged (up to 8-12 h) due to immature hepatic function.
Terminal half-life: 3-4 hours (adults); prolonged in hepatic or renal impairment.
Primarily hepatic metabolism to inactive metabolites; renal excretion of unchanged drug accounts for approximately 1-5%. Biliary excretion is minimal (<5%). Total fecal elimination is negligible (<1%).
Renal excretion of metabolites; <10% unchanged drug. Biliary/fecal elimination minor.
Category C
Category C
Local Anesthetic
Local Anesthetic